The X, our that settlement payment Twist in I'd made million. an wrongdoing agreement reached everyone. settlement Siyuan there or the Glaize Solange admission we of a for agreement, call February originally exchange with XXXX. onetime afternoon Agilent announced claims we of no release of you, Thank update Bioscience, Under liability the in and obtained against of Jim, myself, because afternoon, full none. litigation on terms with $XX.X and like a Chen were filed have this the to good begin contains
legal We through assault to end, survived prepared the in case take only attack. thrived the but trial. this all-out on Twist, an were we we launched Agilent and not to
However, this we to chosen to and jury settle associated the legal have with remove fees uncertainty litigation trial. exceptional the
on is believe all addition, In I'd With in eliminate of best at that, hand. for results to we it first financial to that fiscal of like focus quarter we XXXX. of our our our interest the this the distraction stakeholders business and turn
strong a the a We growth in solid days million in NGS very and are $XXX orders off to synthetic at revenues year-over-year. start, synbio last orders $XX shipping forward, first of And for number yearly in NGS revenues We quarter. which and quarter, reported from the for look the with of both $XX.X rate impressive is million. of a almost million biology looking larger run resulting
to we of quarter we in again see a is the of a fiscal fiscal XXXX, companies that this end the products spend believe need still believe order budget. due exceptional and due our the we We saw to from had team, XXXX. bump it and While we first year bit of their calendar increase to commercial in
not and market to want about incredible $XXX,XXX biopharma. moving vertical are growth. opportunity. reported do I to forward revenues caution And biopharma is This quarter-by-quarter. lumpy excited orders may this the progress be from exceptionally we expect that of grow also We we in very
gross positive Our at essentially XX%, million was flat $X.X margin sequentially.
additional product revenue to to both continue fuel up and As launches for we invest have businesses. synbio new built for capacity we growth NGS, in
Moving to business segments.
quarter, genes shipped XX,XXX primarily from down fourth a the first we quarter, bit holiday in the synbio, about due timing. For to
new which X bringing are will we increased XXXX, capacity. allow calendar of writers half online, first the During
we're processes our turnaround to addition, to continue in resources reduce time. In our in additional point pinch at investing
in improved turnaround stay improving we competitive tail, revenue in double the about our resulting additional year, over to the the market of number on in about first purchase and size while win same the in past to to note, overall. important quarter, time which share. An the X significantly comparison have were smaller Continuing received continue we metric last period years, of orders, XX%, long pursuit this substantial we focus by growth
in to to the we that, track will extensions quantities on product of require We need larger believe, meet allow remain companies large that mid-XXXX us introduce of DNA. line pharmaceutical
on in growth we support clonal-ready our are fragments. introduce long in tail, to to addition, In track the gene calendar XXXX
these will not important serving we to today. near other we subsegment expanding future. products, are X markets meant are very in that be These the With pursue into
For of targeted XX with customers we NGS, first quarter, genomics products the to these our targeted in and enrichment in XXX customers, production. shipped now
of orders first We in of of million, continue good the is in to revenues market reported We year-over-year. $XX.X and which an this increase show quarter. XX% very $X million strong growth
We are rare customers liquid currently diagnostics biopsy, and cancer volume pursuing a within disease. large
[indiscernible] now which conversions X in the Twist's we substantive are after resulted we to going discussed NGS. has As market, SNP microarray
In market. addition, to scope retail include we're expanding our the
few in a emerging NGS is to novel the We like product to to expect again growing take is an greatest that about launches applications proof space. number serve a and continued minutes bioterrorist. talk nature This the the pathogen coronavirus. of I'd
into virus, coronavirus. efficient there's ongoing as amount we As pandemic, worldwide. event before, an enable products have never in a a on Twist to come new work areas an potential of the that emerging seen research key have tremendous customers rapid, Many research like we that
antibody making exists for monitor potential that outbreak NGS the customers making by and exemplifying sequences areas by and work gene specific genes nourishment mutants, are as making custom panels those supporting areas a reason may These today. by that Twist infected. We treatment
secure manner, of protocols take leveraging and our safe delivers fragments. our quickly platform, this procedures. custom customers platform, industry-leading in and which antibody biosecurity Our advantage silicon a genes, do We and panels
health it diagnostics and number just that ordered. in personalized and our we do genes, the resource and our we time large that conditions wide but we not partner, impact and screen coronavirus. makes And government for sustainability. turnaround to Because advanced committee criteria. with product other the support A routinely couple no this, need range and points. of continues of at important every important screen emerging for of synthetic we provide diseases threat in list make United of every XX/X the customers to both therapies. is can fragment sequence all also improve against biosecurity, That and DNA from And terms of that global customers coronavirus, as a all this gene us We single an and of face DNA-based States. as scale, a manufacturing we Importantly, a
customers in to are Because providing ordering very have our biosecurity we doing flags for protocol see we what that known a the of put place regularly, coronavirus We of robust in concern. matches a means dip significant we any sequences. suite the do sequence not a that expect pathogen around a customers revenues offer products from
outflow. this do every not coming of fit do others the situation, and each is day we we our the what in minimize the regular gravity within and want While to
Turning to vertical our market opportunities.
evidenced in a we GPCR efficacy potent leveraging GPCR around shown at on quarter. targets orders this TBXX-X concentrations, we candidate physics-based biopharma, by the a data In conference approach in inhibition way glucose $XXX,XXX We tolerance X discovered in TBXX-X, disease are vivo For antagonist investor and reported rare as and in January, higher of at potential to have company this such this biopharma transforming are is collaboration we therapeutics our the studies, An with a applications are generated business, antibody from severe announced with an like in have a data computational our and the a validate data indications GLP-XR January. complete that, in development platform. as GLP-XR Schrödinger, book mouse study. has hypoglycemia. focused preclinical could
We companies' and any antibody new together potential bringing sharing recover our against are economics. targets X platforms GPCR therapeutics to
complementary excellent diseases. of may therapeutics range the we in an wide of is to example develop This better a way access technologies
a range modest initially. collaboration of that of continued in will opportunities across revenue biopharma, offer expect We generate solutions some wide which expect we we
contracts move take robust time, and encouraged we expect to some by As far. to do and milestones this we royalties. the more expect are We we validation, generate so additional but data include that seeing progress towards are we
we or In data January, DNA selected storage. data as that DNA Molecular projects announced we the Information synthesis Turning the under storage to MIST program. were provider for IARPA Storage
Washington or Microsoft, accessible GTRI, Georgia are of long-term University go Twist. will million, $X.XX make with Roswell $X.X viable years. the contract are X collaborating at to commercial receiving storage additional DNA We X The that is Biotechnologies this next and within the that $XX and to Research commercially the Tech Institute, GTRI to total million million development Twist contract with an would benefit of worth up to with
we a securing working The build its the for design designing our vertical contract, an storage seamless offering. to Twist in commercial the a important subcontract a with our integral to step will be of and are on financial start backing chip is array. DNA produce device with to will we novel IARPA prototypes. synthesis and device data collaborators for efforts collaborate GTRI the As drive
build frequent on cycle the dependent be chip we Finally, data the as cadence next refinement, highly manufacturing is of phase that expect is XX because standard will updates months. chip data our a design, and less design storage upon of storage
the we build As data expertise built Weiss vertical cofounders market. future additional changes leading to specific a responsibilities our infrastructure this and Patrick Banyai, we X NGS will same up, efforts, processes to scale made operations into up COO. growth our this we storage to storage one He enable some in from take [indiscernible] as and businesses, have our our a slow the forward DNA forward. At silicon growth. on Bill the to silicon we him organizational synbio extensive, is ground develop and important time, rapid all to and data future. has become in Bill's and he lead new for platform will of the facilitate look
Jim At our this financial call time, quarter. for over I'd results the like to to review turn the to
